Cargando…

Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer

This study assessed the effects of tislelizumab, a programmed cell death protein 1 inhibitor, in combination with chemotherapy versus chemotherapy alone as first-line treatment on health-related quality of life (HRQoL) in patients with advanced nonsquamous non–small cell lung cancer (nSQ-NSCLC). MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Shun, Yu, Yan, Barnes, Gisoo, Qiu, Xiusong, Bao, Yuanyuan, Tang, Boxiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974185/ https://www.ncbi.nlm.nih.gov/pubmed/35333492 http://dx.doi.org/10.1097/PPO.0000000000000583

Ejemplares similares

The effects of tislelizumab treatment on the health‐related quality of life of patients with advanced non‐small cell lung cancer
por: Huang, Dingzhi, et al.
Publicado: (2023)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
por: Luo, Xia, et al.
Publicado: (2022)

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma
por: Ye, Dingwei, et al.
Publicado: (2020)

Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
por: Liu, Stephen V., et al.
Publicado: (2022)

An Open‐Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non‐Small Cell Lung Cancer
por: Patil, Pradnya Dinkar, et al.
Publicado: (2019)

Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma
por: Serrano, Daniel, et al.
Publicado: (2021)

Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study
por: Jiang, Haiping, et al.
Publicado: (2020)

Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials
por: Langer, Corey J., et al.
Publicado: (2016)

A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer
por: Yabuki, Yohei, et al.
Publicado: (2023)

A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer
por: Huang, Meijuan, et al.
Publicado: (2021)

Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China
por: Gong, Jinhong, et al.
Publicado: (2022)

P1192: ANTI-PD-1 ANTIBODY (TISLELIZUMAB) COMBINED WITH R-CHOP FOR THE TREATMENT OF PREVIOUSLY UNTREATED PRIMARY MEDIASTINAL B-CELL LYMPHOMA: A PROSPENTIVE PHASE II STUDY
por: Mei, Wu, et al.
Publicado: (2023)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
por: Zeng, Xiaohui, et al.
Publicado: (2019)

Pathologic complete response after neoadjuvant tislelizumab and chemotherapy for Pancoast tumor: A case report
por: Tang, Wen‐Fang, et al.
Publicado: (2021)

Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma
por: Ahn, Jae-Sook, et al.
Publicado: (2011)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
por: Fujimoto, Daichi, et al.
Publicado: (2021)

Efficacy and Safety of Low-Dose Nab-Paclitaxel Plus Tislelizumab in Elderly Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
por: Zhu, Wenyu, et al.
Publicado: (2022)

Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer
por: SHIMIZU, TOSHIKI, et al.
Publicado: (2013)

Real‐World longitudinal practice patterns in the use of PD‐1 and PD‐L1 inhibitors as First‐Line therapy in patients with Non‐Small cell lung cancer in the United States
por: Veluswamy, Rajwanth, et al.
Publicado: (2022)

Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer
por: Zheng, Zhiwei, et al.
Publicado: (2022)

Complete remission in a patient with metastatic gastric cancer receiving tislelizumab combined with chemotherapy: a case report
por: Zhu, Zhe, et al.
Publicado: (2023)

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
por: Wang, Jie, et al.
Publicado: (2021)

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)
por: Nadal, Ernest, et al.
Publicado: (2023)

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis
por: Fukuda, Akito, et al.
Publicado: (2022)

Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life
por: Van Cutsem, E., et al.
Publicado: (2022)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
por: Hofman, Véronique, et al.
Publicado: (2022)

Impact of Results of TTF-1 Immunostaining on Efficacy of Platinum-Doublet Chemotherapy in Japanese Patients with Nonsquamous Non-Small-Cell Lung Cancer
por: Nakao, Akira, et al.
Publicado: (2022)

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
por: Pei, Zhengda, et al.
Publicado: (2023)

Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
por: Hayashi, Hidetoshi, et al.
Publicado: (2011)

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
por: Ocvirk, Janja, et al.
Publicado: (2016)

The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis
por: Li, Duo, et al.
Publicado: (2023)

Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China
por: Chen, Ting, et al.
Publicado: (2022)

Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
por: Qiu, Hai‐Bo
Publicado: (2020)

Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy
por: Lin, Gui-Nan, et al.
Publicado: (2016)

Short-term Clinical Outcome of Previously Untreated and Treated Schizophrenia and Impact of Duration of Untreated Psychosis
por: Bansal, Priyanka, et al.
Publicado: (2023)

Previously treated versus untreated scoliosis: are results different?
por: Zaina, Fabio, et al.
Publicado: (2014)

Conversion therapy for advanced penile cancer with tislelizumab combined with chemotherapy: A case report and review of literature
por: Long, Xiang-Yu, et al.
Publicado: (2022)

Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer
por: Kinoshita, A, et al.
Publicado: (2006)

Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review
por: Zhou, Nan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mr1r5dgsgbii63k12ecb98hf5p